Authors


Dennis Bell

Latest:

EPCAM: A Strategy to Enable Manufacturing-Process Control Transformation

Enterprise process control and management (EPCAM) is a new strategy for healthcare manufacturers based on recent process-control breakthroughs in the electronics industry.



Bradley D. Bartels

Latest:

Supplementary Handwashing Techniques to Improve Hand Hygiene

A fluorescence test method was used to visually evaluate handwashing efficacy. Difficult-to-clean areas on skin such as skin folds and webbing between fingers were identified; specific washing techniques to address problem areas are proposed.


Daniela Rožková

Latest:

Rapid Sterility Methods for CAR T-cell Therapies

A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.


TriLink

Latest:

Capping and Manufacturing Strategies for Increasing mRNA Potency and Reducing Costs

In vitro transcription (IVT) is often used to make mRNA, and in co-transcriptional capping an analog cap can be used to cap the mRNA. This paper reviews the recent history of capping analogs in addition to a state-of-the-art approach to improve protein expression.


Thermo Fisher Scientific Pharma Services Group

Latest:

Transforming CDMO partnerships through quality

This whitepaper explores the criteria for defining true quality in a CDMO partnership, including multiple product, process, and relationship variables


John D. Fisher

Latest:

Revolutionizing Biomanufacturing: The Digitalization Advantage

Digital transformation allows for smarter and connected biomanufacturing operations.


Brent Bushnell

Latest:

Contamination Prevention: How Single-Use Systems Can Ensure a Safe, Clean, and Efficient Bioprocess Environment

The authors focus on how single-use systems effectively control three potential sources of common contamination: cross contamination, microbial contamination and biologic contamination of the process facility.


Pharmalex

Latest:

The New Opportunity in Pharmaceutical Outsourcing: Portfolio Maintenance

For decades, the power and potential of outsourcing has been viewed as a way for pharmaceutical companies to gain access to specialized domain expertise across geographic regions and achieve cost savings amidst a highly complex and diverse regulatory environment. In the face of dwindling drug pipelines, complex regulations and block-busters crossing their patent exclusivity, mature products offer a revenue stream for companies to sustain their bottom lines in a hyper-competitive global market.



Coating Place, Inc.

Latest:

Wurster Fluid Bed Coating and Contract Development/Manufacturing with Coating Place, Inc.

Wurster Fluid Bed Coating is one of the most utilized processes for microencapsulation of fine particles in pharmaceutical, dietary supplement, food, and other industries. Jared McDonald walks through a brief history of the invention of the process, what it is, and how it can be used to address specific needs for a product. A discussion of the importance of choosing an experienced CDMO follows.


Eugene J. McNally

Latest:

An Intelligent Drug Development Paradigm

An intelligent drug development paradigm can enable small pharma to implement an effective early drug development approach.


Manali Dalvi

Latest:

Pelletization: Revolutionizing Drug Formulation and Delivery

Pelletization, a popular oral drug delivery method in pharmaceuticals and nutraceuticals, offers numerous benefits. This article delves into the critical parameters for formulation development and technological consideration in pelletization, elucidating its significance in advancing pharmaceutical solutions.


Ashley Wentworth

Latest:

Forecasting Trends in Pharma Innovation

In the coming year, pharmaceutical innovation will be fueled by key trends throughout the quality sector.


Contract Pharmaceuticals Limited (CPL)

Latest:

A Discussion: In Vitro Release Testing and Its Application and Use in Generic Topical

Lucy Zhou, Skin Lab Manager, discusses the importance and applications for utilizing in vitro Release Testing during development of generic topical drug compounds. Lucy discusses how IVRT can play a critical role by saving cost and time during product development and the techniques and applications for using in vitro testing to achieve desired product outcomes.


Tais Conti

Latest:

Reliance-Based Waivers Become the Predominant Trend in In-Country Testing of Pharmaceutical Products

This study reviews changes in in-country testing (registration testing, import testing) requirements and analyzes current trends. In the context of international harmonization of good practices and standards as well as the improved information exchange between national regulatory authorities, in-country testing is considered outdated and redundant in many cases.


Kevin M. Kane

Latest:

An Intelligent Drug Development Paradigm

An intelligent drug development paradigm can enable small pharma to implement an effective early drug development approach.


Nancy G.B. Agrawal

Latest:

Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling

Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.


Siemens

Latest:

Make Paperless Manufacturing a Reality for your Pharmaceutical Facility

Revolutionize pharmaceutical manufacturing through paperless manufacturing. By eliminating paper-based processes, you can quickly centralize your data, reduce cost and time, minimize errors, and release products faster. Even the simplest “paper on glass” digital systems enable streamlined workflows and can ensure real-time data access and seamless communication. Paperless facilities are a reality! Transform your operations today!


Pharmteco

Latest:

Control Strategies and Method Development for Nitrosamines in APIs and Drug Products

Webinar Date/Time: Thu, Nov 7, 2024 9:00 AM PST (12:00 PM EST)


Mark Voaden

Latest:

A Single Adulteration Limit for Cleaning Validation in a Pharmaceutical Pilot-Plant Environment

An adulteration limit of 100 ?g/25cm? (4 ?g/cm?) was proposed for pilot-plant facilities. The dynamic changes in equipment, formulation, and residue determination made implementation of a constantly changing, calculated adulteration limit impractical. A single adulteration limit was simpler to communicate and document, making compliance achievable. The limit would be used only after it was determined to be lower than a health-based evaluation and a visual-cleanliness assessment.


Niamh Panesar

Latest:

Nitrosamine Impurities in Medicinal Products

Industry should improve the standards on application of risk management tools in light of the cases of nitrosamine impurities.



D. López Malo

Latest:

Obtaining simultaneous multiple dissolution profiles of solid oral dosage formulations

Testing the dissolution rates of a pharmaceutical formulation (also known as in vitro availability) aids drug quality control and is a compulsory requirement of the British, European and US pharmacopoeias.


Poonam Kushwaha

Latest:

Extractables and Leachables: An Overview of Emerging Challenges

Extractables and leachables are a growing concern for pharmaceutical manufacturers and regulatory bodies.


Anand Rajan

Latest:

Troubleshooting Using Predictive Maintenance

Smart manufacturing transforms management of tablet and capsule equipment and processes.


Jeffrey Carter

Latest:

Guidelines for Selecting Normal Flow Filters

Proper selection of normal flow filters leads to increased process efficiency from early phase product development through to full-scale biopharmaceutical production.


Moritz Beck-Broichsitter

Latest:

Seven Trends Shaping the Future of Pharmaceutical Formulation Development

Emerging new technologies and disruptive manufacturing concepts are providing new opportunities for pharmaceutical companies.



Prince Sterilization Services, LLC

Latest:

Terminal Sterilization of Sterile Filtered Products

Terminal sterilization of aseptically processed drug products is extremely important for patient safety. As such, it is a regulatory requirement that drug products that can withstand terminal sterilization be terminally sterilized. Overkill type sterilization cycles are not required for a drug manufacturer to make a terminal sterilization claim. Many different time and temperature combinations that are much more product friendly can be used to safely terminally sterilize drug products.